AKTX Akari Therapeutics

$2.00
$-0.10 (-5.00%)

AKTX Stock Analysis Overview

What this means: Akari Therapeutics (AKTX) gets an Overall Rank of 61, which is an above average rank under InvestorsObserver's stock ranking system. Our system considers the available information about the company and then compares it to all the other stocks we have data on to get a percentile-ranked value. AKTX's 61 means that it ranks higher than 61% of stocks.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

Create a FREE account to see full AKTX report

Akari Therapeutics (AKTX) Analyst Forecast

Next 12 months ➝Current Price$2.0052-week High$3.3552-week Low$0.87No Forecast Data Available for AKTX
  • Last Price$2.00
  • Previous Close$2.10
  • Change $-0.10
  • Open$2.11
  • Volume86,159
  • Avg. Volume (100-day)211,178
  • Market Capitalization$57M
  • Days Range $1.97 - $2.12
  • 52-week Range $0.87 - $3.35
  • Dividend Yield
  • Ex. Dividend Date
  • P-E
  • EPS-0.55
  • Earnings Date06/03/2020
  • SectorHealthcare
  • IndustryBiotechnology
  • Avg. Analyst Rec.
  • Beta1.555
  • PEG Ratio
  • Volatility0.77
  • Average True Range0.11
Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing inhibitors of acute and chronic inflammation which includes the complement system, the bioamine system and the eicosanoid system for the treatment of rare and orphan diseases. Its main product candidate includes Coversin, Coversin long acting and Coversin dual action. The firm earns majority of its revenues from United Kingdom. It operates mainly in United States and United Kingdom.